Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2016.

In this issue:

> Message from the CEO

> Adama licenses Priostar^® for 2,4-D

> DEP^TM cabazitaxel shows superior performance

> Starpharma's Targeted DEP^TM conjugates - compelling results in an area of high interest

> AstraZeneca selects second DEP^TM candidate

> Starpharma long standing collaborator ranked 4th in the world

> Starpharma signs licence with Aspen for commercialisation of VivaGel^® BV in Australia and New Zealand

> MOU for VivaGel^® condom in China

> Half-year financial results

> Bio-Europe^® conference

Download: Shareholder Update April 2016 (pdf file, 1MB)

Starpharma today announced that it will present this week at the Bio-Europe^® conference in Stockholm. At the conference Starpharma will also be conducting partnering discussions with pharmaceutical companies for VivaGel^® BV, DEP^TM and other parts of Starpharma’s portfolio.

Starpharma today announced further efficacy results of its most recent DEP™ candidate, DEP™ cabazitaxel, in a human breast cancer model. These data will be presented along with an overview of Starpharma’s DEP™ platform at the BioEurope Spring 2016 conference in Stockholm later this week.

Starpharma and Adama today announced the licensing by Adama of Starpharma's Priostar^® dendrimer technology for the development and commercialization of an enhanced, proprietary 2,4-D herbicide for the US market. 2,4-D is one of the top three herbicides sold world-wide, with global sales in 2014 estimated by Phillips McDougall to be around US$680 million. The US market in 2014 was worth approximately US$115 million, and has been projected by the US Department of Agriculture to grow by more than 70% by 2020.  

"Starpharma is letting Aspen Pharmacare Australia market and distribute its Vivagel BV treatment in Australia and New Zealand for an undisclosed sum. Aspen will market and distribute the treatment for bacterial vaginosis, that's due to be launched in 2016, to clinicians and pharmacies. In return, Starpharma will receive royalties on net sales.

Starpharma still holds the commercialisation rights in the rest of the world."

Go to the article (external link)

Starpharma today announced the signing of a License and Supply Agreement with Aspen Pharmacare Australia Pty Ltd for the sales and marketing of VivaGel^® BV in Australia and New Zealand (ANZ).

Starpharma  today released its interim report and financial results for the half-year ended 31 December 2015.

Financial Summary

• Reported loss of $10.0M (Dec 2014: $8.5M)
• Revenue of $3.7M (Dec 2014: $0.7M)
• R&D tax incentives of $1.8M reported in the half-year (Dec 2014: $1.6M)
• Cash position at 31 December 2015 of $54.7M (June 2015: $30.8M)
• Cash inflows of $7.2M from partners and grants, includes US$2.0M from AstraZeneca and $3.4M R&D tax incentive refund
• Proceeds from completion of $32.0M equity placement

Starpharma today announced the final results of the preclinical study of its HER2-targeted DEP™ conjugate, which achieved complete tumour regression at the last study time point of 120 days post dosing.

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2015.